Pomalidomide-induced lung injury: A case report.

Abstract

RATIONALE:

Pomalidomide is an immunomodulatory imide drug used in multiple myeloma and in Kaposi sarcoma.

PATIENT CONCERNS:

A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation.

INTERVENTION AND OUTCOME:

Antibiotics were started after bronchoscopy. No improvement was noted in dyspnea and biological inflammatory syndrome after 5 days of treatment. Pomalidomide was then discontinued, with continuation of Daratumumab-Dexamethasone, resulting in a rapid recovery of symptoms and CT-scan anomalies. No recurrence of dyspnea was observed during the 15 months of follow-up.

DIAGNOSES:

Pomalidomide-induced lung injury.

LESSONS:

Pomalidomide-induced lung injury is a rare and serious adverse event that can occur early after Pomalidomide introduction. As pomalidomide use is increasing, the identification of drug toxicity as a possible cause of lung injury appears important. We report a rapid recovery of symptoms and CT-scan anomalies after pomalidomide discontinuation.

• Authors: Alexandre Vivien, Julien Ancel, Sophie Godet, Sandra Dury, Jeanne-Marie Perotin, Gaetan Deslee, Claire Launois
• Journal: Medicine (Medicine (Baltimore)) Vol. 102 Issue 2 Pg. e32473 (Jan 13 2023) ISSN: 1536-5964 [Electronic] United States
• PMID: 36637962 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• pomalidomide
• Dexamethasone

Topics

• Male
• Humans
• Aged
• Multiple Myeloma (drug therapy)
• Lung Injury (etiology)
• Dexamethasone (therapeutic use)
• Dyspnea (etiology)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)